Rebecca Abergel

Assistant Professor, Nuclear Engineering
U.C. Berkeley

The threat of a major radiological event presents a danger of not only large-scale external radiation exposure of the population but also internal contamination with radionuclides. Over the past decade, the challenge of limiting human exposure to incorporated radionuclides has given rise to unprecedented interest in developing new therapeutic strategies for radionuclide decorporation. A brief overview of these different approaches will be presented. Development of a new actinide decorporation agent will be summarized, with an accent on the extensive regulatory process guiding such development work. Finally, a perspective on the persisting needs for new decorporation therapeutic options will be given.